Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

726 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Marchetti A, Milella M, Felicioni L, Cappuzzo F, Irtelli L, Del Grammastro M, Sciarrotta M, Malatesta S, Nuzzo C, Finocchiaro G, Perrucci B, Carlone D, Gelibter AJ, Ceribelli A, Mezzetti A, Iacobelli S, Cognetti F, Buttitta F. Marchetti A, et al. Neoplasia. 2009 Oct;11(10):1084-92. doi: 10.1593/neo.09814. Neoplasia. 2009. PMID: 19794967 Free PMC article.
Human telomerase reverse transcriptase mRNA expression assessed by real-time reverse transcription polymerase chain reaction predicts chemosensitivity in patients with ovarian carcinoma.
Buttitta F, Pellegrini C, Marchetti A, Gadducci A, Cosio S, Felicioni L, Barassi F, Salvatore S, Martella C, Coggi G, Bosari S. Buttitta F, et al. Among authors: marchetti a. J Clin Oncol. 2003 Apr 1;21(7):1320-5. doi: 10.1200/JCO.2003.09.065. J Clin Oncol. 2003. PMID: 12663721
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features.
Buttitta F, Barassi F, Fresu G, Felicioni L, Chella A, Paolizzi D, Lattanzio G, Salvatore S, Camplese PP, Rosini S, Iarussi T, Mucilli F, Sacco R, Mezzetti A, Marchetti A. Buttitta F, et al. Among authors: marchetti a. Int J Cancer. 2006 Dec 1;119(11):2586-91. doi: 10.1002/ijc.22143. Int J Cancer. 2006. PMID: 16988931 Free article.
EGFR molecular profiling in advanced NSCLC: a prospective phase II study in molecularly/clinically selected patients pretreated with chemotherapy.
Milella M, Nuzzo C, Bria E, Sperduti I, Visca P, Buttitta F, Antoniani B, Merola R, Gelibter A, Cuppone F, D'Alicandro V, Ceribelli A, Rinaldi M, Cianciulli A, Felicioni L, Malatesta S, Marchetti A, Mottolese M, Cognetti F. Milella M, et al. Among authors: marchetti a. J Thorac Oncol. 2012 Apr;7(4):672-80. doi: 10.1097/JTO.0b013e31824a8bde. J Thorac Oncol. 2012. PMID: 22425916 Free article. Clinical Trial.
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients.
Marchetti A, Palma JF, Felicioni L, De Pas TM, Chiari R, Del Grammastro M, Filice G, Ludovini V, Brandes AA, Chella A, Malorgio F, Guglielmi F, De Tursi M, Santoro A, Crinò L, Buttitta F. Marchetti A, et al. J Thorac Oncol. 2015 Oct;10(10):1437-43. doi: 10.1097/JTO.0000000000000643. J Thorac Oncol. 2015. PMID: 26295376 Free article.
K-ras mutations and cetuximab in colorectal cancer.
Marchetti A, Gasparini G. Marchetti A, et al. N Engl J Med. 2009 Feb 19;360(8):833-4; author reply 835-6. doi: 10.1056/NEJMc082346. N Engl J Med. 2009. PMID: 19228630 No abstract available.
Assessment of EGFR mutations in circulating tumor cell preparations from NSCLC patients by next generation sequencing: toward a real-time liquid biopsy for treatment.
Marchetti A, Del Grammastro M, Felicioni L, Malatesta S, Filice G, Centi I, De Pas T, Santoro A, Chella A, Brandes AA, Venturino P, Cuccurullo F, Crinò L, Buttitta F. Marchetti A, et al. PLoS One. 2014 Aug 19;9(8):e103883. doi: 10.1371/journal.pone.0103883. eCollection 2014. PLoS One. 2014. PMID: 25137181 Free PMC article. Clinical Trial.
726 results